FDA grants fast track status for Forum’s encenicline to treat cognitive impairment in schizophrenia
Encenicline is a new alpha 7 agonist currently in Phase III development to treat cognitive impairment in schizophrenia and Alzheimer’s disease (AD). Recently, the company completed patient enrollment
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.